It is like wedding gifts, right? Emily Post told me I had a full year to get these out… so I am, now.

More substantively, now — there will be a series of comparisons — to Amgen, Libby and likely Baxter and Abbott — and maybe even Amazon’s health units. [Depends on how ambitious I get in the Rockies — while she naps.]

Here is what Pfizer spent on in Q4 — the prior three quarters were detailed here, in more or less real time. Just use the search box, if you are abidingly curious. But I’d call this a spending tie, between Merck and Pfizer (spoiler alert: Amgen blew them both away in 2025 — over $13 million, or by almost 30%). Here is the detail, on Pfizer:

…[Senate:] Vaccine Policy, Coverage and Access; Executive Order 14297 – Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients; H.R. 5256 – 340B Access ACT; Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule; Drug Pricing; PBM Reform; H.R. 4581 – 340B PATIENTS Act of 2025; H.R. 5509 – Safe Step Act; S. 2903 – Safe Step Act; S. 2296 – National Defense Authorization Act (NDAA) for Fiscal Year 2026; S. 1053 – FIGHT China Act; Cancer Research; Centers for Disease Control and Prevention (CDC) Policies….

[US House:] H.R. 5256 – 340B Access ACT; Inflation Reduction Act (IRA): Maximum Fair Price (MFP) Effectuation, Biosimilars Special Rule; H.R. 4581 – 340B PATIENTS Act of 2025; 340B Reform; 340B HHS Pilot Program Model; Insurance Coverage of Prescription Drugs; Direct-to-Patient Prescription Drug Purchase Platforms and insurance coverage; PBM Reform; P.L. 117-169 – Inflation Reduction Act (IRA) of 2022; Drug Pricing; Medicare/Medicaid….

….
[Various Agencies:] International Supply Chain; Global Access; Market Access; Most Favored Nation Policies; Tariffs; Generics; Foreign Freeriding Issues; Non-Tariff Trade Barriers; Trade Issues….

Now you know. Merck, tomorrow — then Amgen; then… Lilly. Grin.

नमस्ते